Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case–control study protocol for dimethyl fumarate-induced lymphopenia

@inproceedings{Kowalec2017ApplicationOP,
  title={Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case–control study protocol for dimethyl fumarate-induced lymphopenia},
  author={Kaarina Kowalec and Elaine Kingwell and Robert Carruthers and Ruth Ann Marrie and Sasha Bernatsky and Anthony Traboulsee and Colin J. D. Ross and Bruce Carleton and Helen Tremlett},
  booktitle={BMJ open},
  year={2017}
}
INTRODUCTION Adverse drug reactions (ADRs) are a global public health issue. The potential for pharmacogenomic biomarkers has been demonstrated in several therapeutical areas, including HIV infection and oncology. Dimethyl fumarate (DMF) is a licensed disease-modifying therapy for the treatment of multiple sclerosis (MS). The use of DMF in MS has been associated with a severe reduction in lymphocyte counts and reports of progressive multifocal leukoencephalopathy. Here, we outline the protocol… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 6 times. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 34 references

PML in a Patient with Lymphocytopenia Treated with Dimethyl Fumarate

The New England journal of medicine • 2015
View 4 Excerpts
Highly Influenced